These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20370621)

  • 41. Emerging resistance in Gram-negative pathogens and implications for clinical practice.
    Cantón R; Lumb J
    Future Microbiol; 2011 Jan; 6(1):19-22. PubMed ID: 21162632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Delivering the payload. Bacterial pathogenesis.
    Stephens C; Shapiro L
    Curr Biol; 1996 Aug; 6(8):927-30. PubMed ID: 8805313
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pilicides-small molecules targeting bacterial virulence.
    Aberg V; Almqvist F
    Org Biomol Chem; 2007 Jun; 5(12):1827-34. PubMed ID: 17551629
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sortase A: an ideal target for anti-virulence drug development.
    Cascioferro S; Totsika M; Schillaci D
    Microb Pathog; 2014 Dec; 77():105-12. PubMed ID: 25457798
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An interview with Kim Orth.
    Orth K
    Trends Biochem Sci; 2013 Jul; 38(7):331-2. PubMed ID: 23768998
    [No Abstract]   [Full Text] [Related]  

  • 46. Anti-virulence Strategies to Target Bacterial Infections.
    Mühlen S; Dersch P
    Curr Top Microbiol Immunol; 2016; 398():147-183. PubMed ID: 26942418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The role of the type-three secretion system of the gram-negative bacteria in regulation of chronic infections].
    Zigangirova NA; Nesterenko LN; Tiganova IG; Kost EA
    Mol Gen Mikrobiol Virusol; 2012; (3):3-13. PubMed ID: 22984766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fourteen years in resistance.
    Livermore DM
    Int J Antimicrob Agents; 2012 Apr; 39(4):283-94. PubMed ID: 22386741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The type VI secretion system: a multipurpose delivery system with a phage-like machinery.
    Records AR
    Mol Plant Microbe Interact; 2011 Jul; 24(7):751-7. PubMed ID: 21361789
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Type III secretion: the bacteria-eukaryotic cell express.
    Mota LJ; Sorg I; Cornelis GR
    FEMS Microbiol Lett; 2005 Nov; 252(1):1-10. PubMed ID: 16216444
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Virulence blocking antibiotics. Anti-bacterial agents with completely new action mechanisms].
    Sundin C; Elofsson M; Wolf-Watz H; Rosell S
    Lakartidningen; 2009 Sep 30-Oct 6; 106(40):2543-5. PubMed ID: 19908625
    [No Abstract]   [Full Text] [Related]  

  • 52. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
    Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Deciphering the role of coumarin as a novel quorum sensing inhibitor suppressing virulence phenotypes in bacterial pathogens.
    Gutiérrez-Barranquero JA; Reen FJ; McCarthy RR; O'Gara F
    Appl Microbiol Biotechnol; 2015 Apr; 99(7):3303-16. PubMed ID: 25672848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hyperstructure interactions influence the virulence of the type 3 secretion system in yersiniae and other bacteria.
    Norris V; Menu-Bouaouiche L; Becu JM; Legendre R; Norman R; Rosenzweig JA
    Appl Microbiol Biotechnol; 2012 Oct; 96(1):23-36. PubMed ID: 22949045
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Type III secretion systems: what is the translocator and what is translocated?
    Blocker A; Holden D; Cornelis G
    Cell Microbiol; 2000 Oct; 2(5):387-90. PubMed ID: 11207594
    [No Abstract]   [Full Text] [Related]  

  • 56. Type III machines of Gram-negative pathogens: injecting virulence factors into host cells and more.
    Anderson DM; Schneewind O
    Curr Opin Microbiol; 1999 Feb; 2(1):18-24. PubMed ID: 10047552
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists.
    Boyd N; Nailor MD
    Pharmacotherapy; 2011 Nov; 31(11):1073-84. PubMed ID: 22026395
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Global antimicrobial resistance in Gram-negative pathogens and clinical need.
    Theuretzbacher U
    Curr Opin Microbiol; 2017 Oct; 39():106-112. PubMed ID: 29154024
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is There Potential for Repurposing Statins as Novel Antimicrobials?
    Hennessy E; Adams C; Reen FJ; O'Gara F
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5111-21. PubMed ID: 27324773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Bacterial communication: quorum-sensing].
    Cakar A
    Mikrobiyol Bul; 2004 Jul; 38(3):273-84. PubMed ID: 15490849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.